HGSI reports mapatumumab data

Human Genome Sciences Inc. (NASDAQ:HGSI) said mapatumumab plus carboplatin and paclitaxel led to no difference in disease response or progression-free survival vs. carboplatin and paclitaxel alone in a Phase II trial for first-line treatment of advanced non-small cell lung cancer (NSCLC). The company plans to present full data this year at a scientific meeting. ...